Safety profile assessment of drug products used for the pathogenetic treatment of COVID19

Objective. To review and summarize literature data in studies of safety of the drug products used for the pathogenetic treatment of COVID-19. Materials and Methods. As the first stage of monitoring the drug’s safety, which are used in the treatment of COVID-19 in Russia, a systematic review of studies of the drug’s safety profiles was carried out: mefloquine, hydroxychloroquine, azithromycin, lopinavir/ritonavir, favipiravir, tocilizumab, olokizumab, baricitinib in the international databases Medline, PubMed, ClinicalTrials.

Current Options for the Pharmacotherapy of the Invasive Candidiasis in Children

Invasive mycoses are the substantial cause of morbidity and mortality in immunocompromised children. The prevalence of invasive mycoses in this population is around 25% and the mortality rates are run up to 55-60%. Invasive candidiasis is a major …